INTRODUCTION
============

Eukaryotic cells use two major strategies for protein degradation, the ubiquitin-proteasome system and autophagy-lysosome pathway. The latter is a highly conserved, lysosome-dependent degradation process. Autophagy isolates cytosolic materials within a double membrane vesicle called an "autophagosome" which then fuses with lysosome to degrade isolated substrates ([@b56-molce-38-5-381]). Until now, more than 30 autophagy-related (ATG) genes and three types of autophagy, macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), have been identified in yeast and mammalian systems ([@b8-molce-38-5-381]; [@b62-molce-38-5-381]). Moreover, various forms of selective autophagy have been characterized. Each is involved in the turnover of different cellular organelles ([@b43-molce-38-5-381]). Defective regulation of the autophagy machinery and/or dysfunction of the lysosomal process can disrupt cellular homeostasis and lead to various disorders ([@b83-molce-38-5-381]). Three major autophagy deregulations have been observed in neurodegenerative diseases: (1) insufficient autophagy activation, (2) autophagy dysfunction due to reduced lysosomal function, and (3) autophagic stress related to pathologic activation of autophagy ([@b12-molce-38-5-381]). These observations indicate that autophagy generally plays an important neuroprotective role.

In this review, the overall mechanism of autophagy, the role of autophagy in neurodegeneration, and recent strategy for identifying therapeutic drugs will be described. Finally, the current strategies for targeting autophagy and the major issues in therapeutic autophagy for neurodegeneration treatment will be discussed.

SEQUESTRATION OF CYTOSOLIC MATERIALS AND AUTOPHAGOSOME MATURATION
=================================================================

For many years, autophagy was considered as a non-selective catabolic process to supply amino acids in response to starvation. Nowadays, however, autophagy is considered to recognize selective target proteins under various stress conditions, while a non-selective catabolic process is accepted in some cases ([@b23-molce-38-5-381]). Macroautophagy is the most widely studied and characterized autophagy process. The cytosolic substrates are sequestered within autophagosomes for lysosomal degradation. In microautophagy, the lysosomal or vacuolar membrane forms invaginations which then are differentiated into the autophagic tube to sequestrate portions of the cytosol for its degradation ([@b47-molce-38-5-381]). During CMA, heat shock cognate (HSC) 70, a chaperone protein, recognizes a pentapeptide, KFERQ, in its cytosolic substrate protein and then binds to a receptor on the lysosomal membrane, LAMP-2A. HSC70 finally unfolds these proteins and translocates directly to the lysosome ([@b38-molce-38-5-381]).

Macroautophagy is initiated through the phosphorylation of the ULK1 complex (ULK1, ULK2, ATG13, FIP200, and ATG101). Depending on cellular energy level, phosphorylation of ULK1 (Ser 758) components, which are involved in the ULK1 complex inhibition, is regulated by mammalian target of rapamycin complex 1 (TORC1), while phosphorylation of ULK1 (Ser 317 and 377) components, involved in ULK1 complex activation, is regulated by AMP-activated protein kinase (AMPK) ([@b57-molce-38-5-381]). Activated ULK1 complex recruits downstream ATG proteins to the autophagosome formation site and phosphorylates beclin 1 (BECN1) on Ser 14, promoting the activity of the VPS34 complex (PI3KCIII, BECN1, ATG14L, and VPS15) to initiate autophagosome formation ([@b77-molce-38-5-381]). During the nucleation process, the VPS34 complex generates phosphatidylinositol 3-phosphate (PI3P). The accumulation of PI3P provides a platform to recruit PI3P-binding proteins ([@b82-molce-38-5-381]). BECN1, a protein essential for the VPS34 complex, has many binding partners such as ATG14L, UVRAG, and BCL2. Through these interacting partners, BECN1 finely regulates autophagy under different stress conditions ([@b1-molce-38-5-381]). When the nucleation step starts, the autophagosome membrane is expanded.

In the elongation process, the autophagosome membrane around the cytoplasmic substrates requires two ubiquitin-like systems to extend the membrane. In the Atg5-Atg12 conjugation system, Atg12 was identified as the first ubiquitin-like protein (Ubl). Atg12 is activated by the E1-like enzyme, Atg7, and is transferred to the E2-like enzyme, Atg10, on its target protein Atg5. Finally, Atg5-Atg12 interacts with Atg16 to form a dimeric complex. The Atg5-Atg12-Atg16 complex targets the membranes depending on the formation of PI3P ([@b85-molce-38-5-381]). The second ubiquitin-like conjugation system is the Atg8 conjugation system. Atg8 is cleaved by the cysteine protease, Atg4, and is processed by the ubiquitin-like enzymes, Atg7 and Atg3. The conjugated Atg8-phosphatidylethanolamine (PE) resides on the phagophore membrane and participates in cargo recruitment to the autophagosome ([@b102-molce-38-5-381]). In the maturation process, the cargo sequestration is completed and the autophagosome fuses with lysosomes to degrade its cargo. Recent studies have implicated SNARE proteins, endosomal COPs, ESCRT III complex, small GTPase Rab proteins, chaperone HSP70 family proteins, and TECPR1 as crucial components in autophagosome maturation ([@b11-molce-38-5-381]; [@b33-molce-38-5-381]; [@b61-molce-38-5-381]). In the final step of autophagy, the cargo is broken down and degraded to cellular components and then released into the cytosol.

CHARACTERISTICS OF NEURONAL AUTOPHAGY
=====================================

In general, the autophagic process has been reported to protect the neurons. Neuronal autophagy is essential for synaptic plasticity, anti-inflammatory function in glial cells, oligodendrocyte development, and myelination process ([@b39-molce-38-5-381]; [@b44-molce-38-5-381]). The aggregate-prone proteins in neurons cannot be diluted by cell division because neurons are post-mitotic cells. Thus, neurons require well-regulated protein quality control systems. Accordingly, altered activity of the protein degradation system causes the accumulation of abnormal proteins and eventually leads to neuronal dysfunction such as deregulated transcription and impaired axonal transport ([@b55-molce-38-5-381]). Increasing evidence shows that autophagy is implicated in neuronal disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic lateral sclerosis (ALS), and Multiple sclerosis (MS). In this review, we will summarize and discuss the relationship between autophagy and these neurodegenerative disorders.

AUTOPHAGY IN NEURODEGENERATION
==============================

Regulation of autophagy in Alzheimer's disease (AD)
---------------------------------------------------

AD is the most common type of progressive dementia. In the early stages, the patient has difficulty in remembering recent events. As the disease advances, confusion, irritability, aggression, mood swings, and trouble with reading and writing are displayed ([@b100-molce-38-5-381]). AD is characterized by two abnormal structures, senile plaques and intra-neuronal fibrillary tangles. Amyloid plaques consist of largely insoluble toxic protein peptides, beta-amyloid peptides (Aβ), which are generated by the enzymatic cleavage of a larger protein, amyloid precursor protein (APP) ([@b72-molce-38-5-381]). Neurofibrillary tangles consist of highly phosphorylated forms of the microtubule-associated protein tau. Tau can interact with tubulin to stabilize microtubules and controls the vesicle transport in neurons. When this protein is abnormally hyperphosphorylated by tau kinases, tau is prone to aggregate into paired helical filaments forming neurofibrillary tangles ([@b101-molce-38-5-381]).

The first evidence that autophagy may be involved in the pathogenesis of AD came from the observation of numerous autophagic vacuoles (AVs) in AD brains. Using immunogold-labeling and electron microscopy, striking accumulation of immature AVs were observed in dystrophic neurites ([@b65-molce-38-5-381]). The purified AVs contained APP and beta-cleaved APP. These vacuoles are highly enriched with presenilin-1 (PS1) and nicastrin together with Aβ. Along with this observation, additional evidence suggests that the transport of AVs and autophagosome-lysosome fusion may be impaired in AD. Because the retrograde transport of autophagosomes along the axon is crucial for the fusion with lysosomes in neurons, the impaired retrograde transport of autophagosomes leads to the accumulation of immature AVs and Aβ-generating AV in AD ([@b97-molce-38-5-381]; [@b103-molce-38-5-381]), leading to enhanced Aβ production. In addition, Aβ was also shown to regulate autophagy by inducing the formation of AVs through AMPK activation ([@b86-molce-38-5-381]) and to induce autophagy through lipid raft-localized BECN1 ([@b60-molce-38-5-381]).

There is an interesting report showing a gamma-secretase-independent function of PS1 in lysosome. Although PS1 is a critical component of the APP-cleaving gamma-secretase complex, [@b45-molce-38-5-381] showed that PS1 mutations worsen lysosomal function and promote neuronal loss. In PS1 null blastocysts, substrate proteolysis and autophagosome clearance are inhibited as a result of lysosomal dysfunction, which is caused by the failure of PS1-dependent targeting of v-ATPase V0a1 subunit to lysosomes. Together with UPS, autophagy is known to play a role in the clearance of soluble monomeric and oligomeric tau and insoluble tau aggregates. In particular, inhibition of autophagosome-lysosome fusion by chloroquine causes a delay in tau clearance and the accumulation of tau aggregates ([@b30-molce-38-5-381]). Among the various forms of tau, phosphorylated tau is affected by the failure of autophagy ([@b74-molce-38-5-381]). In addition, truncated tau, which is found in AD brains ([@b27-molce-38-5-381]), is cleared by autophagy in the tetracycline-inducible model, whereas full-length tau is degraded by the proteasome ([@b19-molce-38-5-381]). Furthermore, BECN1 downregulation is observed in early AD ([@b69-molce-38-5-381]) and is caused by caspase-cleavage ([@b75-molce-38-5-381]). BECN1 reduction impairs retromer trafficking and phagocytosis in microglia ([@b50-molce-38-5-381]), affects APP processing in neurons ([@b34-molce-38-5-381]), and increases Aβ deposition and neurodegeneration in APP transgenic mouse, an AD model ([@b69-molce-38-5-381]). Evidence shows a pivotal role of autophagy in Aβ accumulation and the formation of neurofibrillary tangles.

Because most neurodegenerative diseases are caused by abnormal protein aggregation, new discovery that can enhance the degradation of toxic aggregates is essential for effective therapy. Thus, autophagy, which is mainly responsible for the degradation of abnormal proteins or organelles, is considered as an emerging therapeutic target. Moreover, autophagy plays a protective role against various stress stimuli and apoptotic insults ([@b28-molce-38-5-381]). Thus, the identification of autophagy inducers can be a good therapeutic strategy. Recently, non-toxic small-molecules that can restore basal-level of autophagy in neurons have been studied. Autophagy-inducing compounds show substantial therapeutic effects on various neurodegenerative disease animal models. Rapamycin, a selective inhibitor of TORC1, ameliorates Aβ and tau pathology in an AD mouse model ([@b10-molce-38-5-381]). Latrepirdine, also known as dimebon, stimulates Atg5-dependent autophagy in the mouse brain and reduces Aβ neuropathology ([@b90-molce-38-5-381]). Protein phosphatase 2A (PP2A) agonist, metformin, inhibits tau hyperphosphorylation through inhibiting TORC1 and is currently tested in clinical trials for AD ([@b40-molce-38-5-381]). In addition, SMER28, small-molecule enhancer of rapamycin 28, greatly decreases the level of Aβ peptide and APP-CTF in a gamma-secretase-independent manner ([@b95-molce-38-5-381]).

Autophagy can also be induced by activating the ULK1 kinase, AMPK, in a TORC1-independent manner. Recently, various experimental and clinical trials have suggested that lithium may ameliorate AD pathogenesis through a combination of mechanisms that includes AMPK activation and the regulation of autophagy ([@b25-molce-38-5-381]). Resveratrol and its analogs, RSVA314 and RSVA405, have multiple molecular actions that include AMPK activation and show protective effect against AD ([@b98-molce-38-5-381]). Nicotinamide prevents pathology and cognitive decline through enhancing lysosome/autophagosome acidification to reduce autophagosome accumulation in an AD mouse model ([@b49-molce-38-5-381]). Even though the pathologic evidence is not sufficient in AD, virally packaged BECN1 and small-molecule BECN1 mimetics can also reduce the accumulation of toxic aggregates by targeting the early stage of autophagy ([@b84-molce-38-5-381]). It appears that, in the early stage of AD, autophagy-inducing agents can prevent the accumulation of plaques and tangles by degrading these aggregates. However, autophagy promotion can aggravate the pathologies in the late stage of AD in which autophagosome/lysosome fusion or lysosomal function is impaired ([@b13-molce-38-5-381]). Therefore, new strategies that can enhance the fusion of autophagosome/lysosome and the lysosomal activity will be essential for advanced AD therapy.

Regulation of autophagy in Parkinson's disease (PD)
---------------------------------------------------

PD is a chronic and progressive movement disorder. PD symptoms develop gradually over time. PD results from the death of vital nerve cells in the brain and primarily affects the substantia nigra. During PD development, the amounts of dopaminergic neurons are decreased in the substantia nigra ([@b92-molce-38-5-381]). PD is well-characterized by the accumulation of α-synuclein (SNCA) and ubiquitin into intracytoplasmic inclusions called Lewy bodies. Most PD cases are sporadic, meaning that they occur with unknown etiology and only 5% of PD cases are hereditary, due to mutations of at least 6 genes, SNCA, Parkin (PARK2), β-glucocerebrosidase (GBA), PTEN-induced putative kinase 1 (PINK1), DJ1, and leucine-rich repeat kinase 2 (LRRK2) ([@b2-molce-38-5-381]).

The autophagic degeneration in melanized neurons of the substantia nigra in patients with PD provides evidence that autophagy is related to PD ([@b5-molce-38-5-381]). Emerging evidence then implicated that proteins encoded by PD-related genes can regulate autophagy pathways. Macroautophagy, chaperone-mediated autophagy (CMA), and mitophagy are involved in PD. SNCA level is a major determinant of its neurotoxicity and is related to the formation of Lewy bodies. Thus, SNCA degradation is essential in PD therapeutics. Recent studies indicate that deubiquitinated SNCA is mainly degraded by autophagy, while monoubiquitinated SNCA is preferentially removed by the proteasome ([@b67-molce-38-5-381]). In SNCA transgenic mice, the ubiquitin-proteasome system is the main degradation pathway for SNCA under normal conditions, while autophagy is functional against increased intracellular SNCA ([@b22-molce-38-5-381]). Mutations in the *LRRK2* gene were first identified in 2004 in families with autosomal-dominant PD and G2019S mutation in LRRK2 is now found not only in 5--6% of familial PD, but also in 1--2% of patients with sporadic PD ([@b7-molce-38-5-381]). Several reports indicated that LRRK2 might regulate macroautophagy. LRRK2 knockdown increases the autophagic flux under starvation conditions and inhibition of LRRK2 kinase activity stimulates macroautophagy in the absence of any alteration of TORC1 ([@b3-molce-38-5-381]; [@b51-molce-38-5-381]).

Mitophagy is also known to be linked with the function of several autosomal recessive PD-related genes. Wild-type Parkin, a cytosolic E3-like ligase, mainly localizes in the cytosol in the resting state and, following treatment with a mitochondrial uncoupler (CCCP), translocates to damaged mitochondria for clearance ([@b63-molce-38-5-381]). Thus, mutations in Parkin, which causes early-onset familial and sporadic PD, abolish the ability to clear damaged mitochondria through mitophagy. Further, studies revealed that depolarization of mitochondria triggers PINK1 accumulation on the outer membrane of damaged mitochondria to recruit Parkin. Parkin then labels some mitochondrial proteins such as VDAC and MFN with ubiquitin on the mitochondria, leading to the recruitment of several autophagy components, including p62, for the degradation of damaged mitochondria by mitophagy ([@b80-molce-38-5-381]). However, despite extensive investigations, the direct connection between mitophagy and the cause of PD remains elusive.

Macroautophagy is not the only lysosomal degradation pathway responsible for SNCA degradation. Indeed, SNCA can be degraded through CMA. SNCA protein contains a KFERQ-like motif. Thus, SNCA is recognized by HSC70 chaperone and LAMP2A receptor for its degradation via the CMA pathway. Surprisingly, both pathogenic mutant forms of SNCA (A30P, A53T) and dopamine-modified SNCA can bind to LAMP2A, but fail to translocate to lysosomes ([@b53-molce-38-5-381]). A recent study shows that LRRK2 can also be degraded in lysosomes by CMA, whereas the most common pathogenic mutant form of LRRK2 (G2019S) is rarely degraded by CMA ([@b66-molce-38-5-381]).

In addition, oxidative stress, which is a key contributor in the loss of dopaminergic neurons, is known to cause PD. Thus, decreasing oxidative stress through autophagy can be an effective PD therapeutic strategy ([@b91-molce-38-5-381]). Antioxidants such as thiols, ascorbic acid, and polyphenols, eliminate free radical intermediates and inhibit oxidation reaction. The ideal antioxidant for PD therapy should have both aberrant ROS clearing and autophagy-inducing properties because certain levels of oxidative stress are necessary to activate autophagy. Several polyphenols can be effective PD therapeutic agents because they can induce autophagy as well as reducing oxidative stress. For example, resveratrol partially protects rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through autophagy activation ([@b48-molce-38-5-381]). Kaempferol and celastrol also prevent rotenone-mediated acute toxicity by increasing autophagy in SH-SY5Y cells ([@b24-molce-38-5-381]; [@b18-molce-38-5-381]). Moreover, curcumin, a diaryheptanoid possessing antioxidant properties, ameliorates the neurotoxicity in the A53T SNCA cell model of PD through recovery of macroautophagy ([@b36-molce-38-5-381]).

Because the basal level of autophagy is essentially required for maintaining neuronal homeostasis, enhancement of basal autophagy is explored as a therapeutic target. First of all, BECN1 gene transfer ameliorates the neurodegenerative pathology in the SNCA model of PD ([@b88-molce-38-5-381]). Overexpression of RAB1A, a key regulator of intracellular membrane trafficking and autophagosome assembly, was shown to partially improve motor deficits in SNCA-expressing dopaminergic neurons ([@b15-molce-38-5-381]). Histone deacetylase 6 (HDAC6), which controls autophagosome maturation, is able to suppress SNCA-induced dopaminergic neuronal loss in drosophila ([@b20-molce-38-5-381]). In addition, transcription factor EB (TFEB) overexpression rescues dopamine neurons via autophagic clearance of SNCA oligomers ([@b17-molce-38-5-381]). At last, reduced levels of LAMP2A and HSC70 protein, the major components of CMA, have been observed in the brain of patients with PD. Thus, these findings provide a significant role of autophagy in the pathogenesis of PD. Autophagy represents a good target for PD therapeutics ([@b78-molce-38-5-381]).

Regulation of autophagy in Huntington's disease (HD)
----------------------------------------------------

HD is a neurodegenerative disorder that is characterized by the loss of motor control and cognitive dysfunction. HD is caused by damages to the subcortical part of the forebrain, the striatum, which plays a key role in body movements. HD is an autosomal dominant disease caused by the expansion of a CAG (cytosine-adenine-guanine) triplet repeat in exon 1 of the gene encoding huntingtin (HTT) protein. The polyglutamine (polyQ) tract in the mutant HTT protein encoded from the CAG repeat is responsible for the formation of toxic oligomers and aggregates. Whether these aggregates are toxic remain to be elucidated ([@b52-molce-38-5-381]). The expansion of the HTT polyQ tract is 6--34 in normal individuals and 36--121 in affected individuals. The longer the length of tandem repeats in mutant HTT is, the easier it is to form aggregates and the earlier is the age of HD onset ([@b37-molce-38-5-381]). On the other hand, wild-type HTT function is not yet well-elucidated, but is essential for embryonic development ([@b21-molce-38-5-381]). Therefore, HD therapeutic approach should consider the importance of selectivity without interfering with wild-type HTT.

Mutant HTT forms perinuclear cytoplasmic aggregates and intracellular inclusions, which can be removed by autophagy. Previous studies have shown that autophagy induces the degradation of both aggregated and soluble forms of HTT and decreases toxicity in cell, fly, and mouse models of HD ([@b73-molce-38-5-381]). Moreover, autophagy alteration has been observed in various types of HD models such as primary striatal neurons from HD mice or lymphoblasts of patients with HD ([@b59-molce-38-5-381]). In general, inefficient macroautophagy is known to contribute to HD pathogenesis. More specifically, the ability of AVs to recognize cytosolic cargos is largely defective in HD cells. The autophagosome-lysosome pathway is normal or even increased in HD cells, but AVs fail to efficiently recognize and trap cytosolic cargos due to the interaction between mutant HTT and p62 ([@b54-molce-38-5-381]). In addition, the accumulated mutant HTT can recruit cytosolic BECN1 and impairs BECN1 complex-mediated autophagy, causing the accumulation of mutant HTT and leading to neuronal toxicity in patients with HD ([@b81-molce-38-5-381]).

Increasing evidence supports the fact that HTT is also degraded by CMA. While CMA activity increases in response to macroautophagy dysfunction in the early stages of HD, this compensatory CMA activity continuously decreases with aging, leading to the onset of pathological symptoms ([@b42-molce-38-5-381]). There is a KFERQ-like motif in the HTT fragment (1--552) ([@b71-molce-38-5-381]), raising the possibility that HTT can be affected by CMA. This notion is also in line with the observation that HSP70 and its co-chaperone, HSP40, modulates polyQ aggregation by partitioning monomeric conformations ([@b99-molce-38-5-381]). Accordingly, LAMP2A is involved in the chaperone/HTT clearance. A study showed that HTT is phosphorylated by IκB kinase and the phosphorylated HTT can be better cleared by LAMP2A and HSP70-mediated CMA through additional post-translational modifications ([@b94-molce-38-5-381]).

HD pathogenesis is strongly influenced by neuronal autophagy dysfunction. However the molecular events, leading to autophagy dysfunction, remain elusive. Many therapeutic approaches to treat HD are under development to manipulate autophagy. Several reports suggest that autophagy activation alleviates behavioral motor abnormalities and neuropathology in HD model systems ([@b14-molce-38-5-381]). Rapamycin and its analog CCI-779 reduce polyQ toxicity and improve behavioral motor phenotypes in a HD mouse model ([@b73-molce-38-5-381]). Furthermore, mTOR-independent autophagy enhancer enhances HTT clearance and ameliorates HD motor phenotype. Trehalose, a disaccharide present in many non-mammalian species, induces macroautophagy in an mTOR-independent manner and ameliorates polyQ-mediated pathology in a HD mouse model ([@b93-molce-38-5-381]). Similarly, rilmenidine, an imidazoline-1 receptor agonist, induces mTOR-independent autophagy and reduces the pathologic signs of the disease in a HD mouse model ([@b76-molce-38-5-381]). In addition, N(10)-substituted phenoxazine safely upregulates autophagy in an AKT- and mTOR-independent fashion in neurons. In a HD neuron model, N(10)-substituted phenoxazine is neuroprotective and decreases the accumulation of aggregated mutant HTT ([@b96-molce-38-5-381]). Inhibition of histone deacetylase (HDAC) has also been considered as a therapeutic strategy for HD. HDAC6 was previously shown to be an essential link between autophagy activation and the UPS impairment to reduce neurodegeneration ([@b68-molce-38-5-381]). The HDAC1 and HDAC3 inhibitor, 4b, ameliorates cognitive decline and HD-related phenotypes in the striatum and cortex of R6/2 mice ([@b35-molce-38-5-381]). Moreover, research is underway to identify potent and selective HDAC inhibitors as potential drugs for HD treatment ([@b9-molce-38-5-381]).

Regulation of autophagy in Amyotrophic lateral sclerosis (ALS)
--------------------------------------------------------------

ALS, often referred to as "Lou Gehrig's disease" is a motor neuron disease that is caused by a selective loss of upper and lower motor neurons in the brain and spinal cord. The progressive degeneration of motor neurons in ALS eventually leads to death due to respiratory failure. The most common form of ALS is a sporadic type and only about 5--10% of all ALS cases are hereditary. Since 1993, several genes associated with both familial ALS and sporadic ALS, have been identified, including superoxide dismutase 1 (SOD1), RNA-binding protein FUS, and TAR DNA-binding protein 43 (TDP43) ([@b4-molce-38-5-381]). Many factors such as oxidative stress, mitochondrial dysfunction, abnormalities of the immune system, and glutamate toxicity are known to cause sporadic ALS ([@b41-molce-38-5-381]).

Recently, dysfunction of the autophagic/lysosomal system was also shown to be tightly associated with ALS. The first evidence came from the SOD1G93A-expressing ALS mouse model. Although autophagy seems impaired in the ALS model, many researchers showed its induction in ALS mouse models ([@b58-molce-38-5-381]; [@b87-molce-38-5-381]). In patients with sporadic ALS, the autophagy features were observed under electron microscopy in the cytoplasm of normal motor neurons and more frequently in degenerated motor neurons ([@b79-molce-38-5-381]). However, this feature cannot ensure which factor causes the enhancement of LC3-II in ALS. Despite some controversy regarding the role of autophagy in ALS, many studies suggest that autophagic clearance of mutant SOD1 is beneficial to ALS ([@b46-molce-38-5-381]). Small heat shock protein B8 (HSPB8) decreases the aggregation of mutant SOD1 and increases its solubility and clearance by enhancing autophagy without affecting wild-type SOD1 turnover in the SOD1G93A ALS model mice ([@b16-molce-38-5-381]). A dramatic decrease in mutant SOD1 toxicity was also observed in X-box-binding protein-1 (XBP-1), a key molecule in unfolded protein response, deficient mice, correlating with the increased levels of autophagy and the reduced accumulation of mutant SOD1 aggregates in the spinal cord ([@b32-molce-38-5-381]). Furthermore, autophagy-linked FYVE (Alfy) promotes the autophagic degradation of misfolded proteins involved in ALS. In this study, Alfy overexpression decreases the expression of mutant proteins through autophagy and reduces mutant protein toxicity ([@b31-molce-38-5-381]). On the other hand, mutant SOD1 transgenic mice haploinsufficient for BECN1 show an unexpected increase in lifespan ([@b64-molce-38-5-381]), showing a pathogenic and opposite role of BECN1 in the development of ALS.

Additionally, functions of several ALS-related genes were reported to be associated with autophagy. ALS2/alsin is a guanine nucleotide exchange factor for the small GTPase Rab5 and is involved in micropinocytosis-associated endosome fusion and trafficking. Recently, ALS2 loss has been shown to exacerbate SOD1H46R-mediated neurotoxicity by disturbing endosome-autophagosome trafficking ([@b29-molce-38-5-381]). Another protein mutation causing ALS is TDP43, a nuclear RNA-binding protein involved in several aspects of RNA processing. TDP43 turnover is known to be enhanced by autophagy activation and that autophagy-activating compounds improve TDP43 clearance and enhance survival in neuronal ALS models ([@b6-molce-38-5-381]).

Unlike other neurodegenerative disorders, the identification of autophagy-regulating drugs as potential ALS therapeutic agents is not much studied. Like other diseases, however, autophagic degradation of mutant SOD1 and TDP43 is believed to be beneficial to ALS. Therefore, several autophagic enhancers such as rapamycin, lithium, and trehalose are expected to function as pathology reliever in ALS. In general, rapamycin plays a neuroprotective role in several neurodegenerations. However, in ALS models, it showed beneficial and detrimental effects in various studies. Rapamycin accelerates motor neuron degeneration and shortens the lifespan of SOD1G93A mice ([@b104-molce-38-5-381]). In contrast, rapamycin moderately increases the survival of ALS mice deficient of mature lymphocytes. ([@b89-molce-38-5-381]). In a recent study, mTOR-independent autophagy enhancer, trehalose, decreased SOD1 and p62 aggregation, reduced ubiquitinated protein accumulation, and inhibited the proapoptotic pathway in SOD1G93A mice ([@b105-molce-38-5-381]). Lithium also shows both protective and detrimental effects in ALS models. Lithium delay disease progression in patients with ALS. Moreover, it showed neuroprotective effects and delayed the disease onset and duration in the SOD1G93A ALS mouse model ([@b26-molce-38-5-381]). In contrast, under the same conditions, another group showed that lithium does not ameliorate disease progression in SOD1G93A mice (C57BL/6J or 129S2/Sv strains) ([@b70-molce-38-5-381]). While this aspect needs to be further characterized using animal genetic models, combination strategies or modified autophagy enhancers may still be appropriate as ALS therapeutic approaches.

CONCLUSION
==========

Accumulated evidence revealed that neuronal autophagy is essential for the healthy aging of neurons. Moreover, neuronal autophagy is the major process for the degradation of an abnormal protein aggregate, which is the major cause of most neurodegenerative diseases such as AD, PD, HD, and ALS. Increasing research in autophagy revealed several links connecting autophagy and neurodegenerative diseases. However, direct links and molecular mechanisms remain elusive and need to be further addressed. Impairment of lysosomal function or autophagosome/lysosome fusion is observed in most neurodegenerative disorders. Nevertheless, the recent attempts to treat the autophagic impairment in neurodegeneration have focused on the induction of initial autophagy. Therefore, it is critical to overcome lysosomal dysfunction when developing therapeutic strategies against neurodegenerative diseases. Research on autophagy as a potential therapeutic target for neurodegenerative disease treatment is only starting. Some compounds for the treatment of AD have been tested in human clinical trials. Other compounds for the treatment of the other neurodegenerative diseases are now in the preclinical phase. Despite research limitations, therapeutic approaches targeting autophagy are highly expected to contribute to the treatment of neurodegenerative diseases.
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Autophagy-enhancing compounds that therapeutically targets neurodegenerative diseases

  Disease                            Autophagy target           Compound                  Clinical trial phase    References
  ---------------------------------- -------------------------- ------------------------- ----------------------- -----------------------
  AD                                 TORC1 inhibition           Rapamycin                                         [@b10-molce-38-5-381]
  SMER28                                                        [@b95-molce-38-5-381]                             
  Metformin                          Clinical trial phase II    [@b40-molce-38-5-381]                             
  Latrepirdine                       Clinical trial phase III   [@b90-molce-38-5-381]                             
  Resveratrol                        Clinical trial phase III   [@b98-molce-38-5-381]                             
  RSVA314, 405                                                  Vingtdeux et al., 2011                            
  AMPK activation                    Lithium                    Clinical trial phase II   [@b25-molce-38-5-381]   
  BECN1 complex lysosomal function   BECN1 mimetics                                       [@b84-molce-38-5-381]   
  Nicotinamide                       Clinical trial phase I     [@b49-molce-38-5-381]                             
  PD                                 TORC1 inhibition           Resveratrol                                       [@b48-molce-38-5-381]
  Kaempferol                                                    Filomenin et al., 2012                            
  Celastrol                                                     [@b18-molce-38-5-381]                             
  Curcumin                                                      [@b36-molce-38-5-381]                             
  BECN1 complex                      BECN1 gene                                           [@b88-molce-38-5-381]   
  Vesicle transport                  RAB1A gene                                           [@b15-molce-38-5-381]   
  HDAC regulation                    HDAC6 gene                                           [@b20-molce-38-5-381]   
  TFEB regulation                    TFEB gene                                            [@b17-molce-38-5-381]   
  HD                                 TORC1 inhibition           Rapamycin                                         [@b73-molce-38-5-381]
  CCI-779                                                       [@b73-molce-38-5-381]                             
  AMPK activation                    Trehalose                                            [@b93-molce-38-5-381]   
  Rilmenidine                                                   [@b76-molce-38-5-381]                             
  10-NSP                                                        [@b96-molce-38-5-381]                             
  HDAC regulation                    HDAC inhibitors                                      [@b9-molce-38-5-381]    
  ALS                                TORC1 inhibition           Rapamycin                                         [@b89-molce-38-5-381]
  AMPK activation                    Lithium                                              [@b26-molce-38-5-381]   
  Trehalose                                                     [@b105-molce-38-5-381]                            
